XML 105 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 16, 2022
Dec. 30, 2022
Jun. 16, 2022
Dec. 31, 2021
Dec. 25, 2020
Sep. 14, 2022
Schedule of Intangible Asset by Major Class [Line Items]            
Other Asset Impairment Charges   $ 0.0 $ 0.0 $ 154.9 $ 63.5  
Intangible asset amortization   318.7 281.8 581.1 771.2  
Amortizable:            
Finite-lived intangible assets, gross $ 2,918.9 3,041.2 2,918.9 10,601.8    
Accumulated amortization   318.7   5,269.4    
Non-Amortizable:            
Indefinite-lived intangible assets, gross 233.3 121.3 233.3 116.0    
Asset Impairment Charges   0.0 0.0 154.9 $ 63.5  
Intangible Assets, Gross (Excluding Goodwill) 3,152.2   3,152.2      
Trademarks            
Non-Amortizable:            
Indefinite-lived intangible assets, gross   0.0   35.0    
In-process research and development            
Non-Amortizable:            
Indefinite-lived intangible assets, gross   121.3   81.0    
Completed Technology            
Amortizable:            
Finite-lived intangible assets, gross   3,041.2   10,404.0    
Accumulated amortization   318.7   5,160.4    
Licensing Agreements            
Amortizable:            
Finite-lived intangible assets, gross   0.0   120.1    
Accumulated amortization   0.0   82.1    
Trademarks            
Amortizable:            
Finite-lived intangible assets, gross   0.0   77.7    
Accumulated amortization   $ 0.0   $ 26.9    
Acthar Gel (1)            
Amortizable:            
Finite-lived intangible assets, gross $ 1,069.0   $ 1,069.0      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 13 years 6 months          
Acthar Gel (1) | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.20%   14.20%      
Therakos            
Amortizable:            
Finite-lived intangible assets, gross $ 913.8   $ 913.8      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 10 years          
Therakos | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.00%   14.00%      
Amitiza            
Amortizable:            
Finite-lived intangible assets, gross $ 84.5   $ 84.5      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 3 years          
Amitiza | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.00%   14.00%      
Inomax            
Amortizable:            
Finite-lived intangible assets, gross $ 652.9   $ 652.9      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 9 years          
Inomax | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.00%   14.00%      
StrataGraft [Member]            
Amortizable:            
Finite-lived intangible assets, gross $ 56.8   $ 56.8      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 11 years          
StrataGraft [Member] | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.00%   14.00%      
Generics            
Amortizable:            
Finite-lived intangible assets, gross $ 71.4   $ 71.4      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 5 years          
Generics | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 13.30%   13.30%      
APAP            
Amortizable:            
Finite-lived intangible assets, gross $ 70.5   $ 70.5      
Non-Amortizable:            
Finite-lived intangible assets - useful lives 20 years 6 months          
APAP | Finite-Lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 13.00%   13.00%      
Terlipressin [Member]            
Non-Amortizable:            
Indefinite-lived intangible assets, gross $ 104.8   $ 104.8     $ 104.8
Terlipressin [Member] | Indefinite-lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 15.00%   15.00%      
Generics IPR&D            
Non-Amortizable:            
Indefinite-lived intangible assets, gross $ 128.5   $ 128.5      
Generics IPR&D | Indefinite-lived Intangible Assets            
Non-Amortizable:            
Discount Rate, Present Value of Future Cash Flows 14.00%   14.00%      
Terlivaz            
Non-Amortizable:            
Finite-lived intangible assets - useful lives 7 years          
Terlivaz | Completed Technology            
Amortizable:            
Finite-lived intangible assets, gross           $ 17.5